Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue.
Three 18F labeled fluoronitroimidazoles have been prepared as potential in vivo markers of hypoxic cells in tumors, and ischemic areas of the heart and brain. 1-(2-Nitroimidazolyl)-3-[18F]fluoro-2-hydroxypropanol (18F]fluoro-normethoxymisonidazole) 4, 1-(2-[18F]fluoroethyl)-2-nitroimidazole 7, and 1-(2-[18F]-fluoroethyl)-2-methyl-5-nitroimidazole ([18F]fluoro-norhydroxymetronidazole) 10 were prepared in average radiochemical yields of less than 1%, 23% and 15-43% (8% at the no carrier-added level) respectively at end-of-synthesis. The in vivo biodistribution in rats was determined for each of the 18F labeled fluoronitroimidazoles. At 1 and 3 h after administration, the tissue distribution of each of the 18F labeled nitroimidzaoles was quite uniform and consistent with that of nitroimidazoles previously studied. These results suggest the need for a suitable animal model to evaluate their potential as in vivo markers of hypoxic tissue in the brain.
D000818:Animals; D005461:Fluorine; D000860:Hypoxia / Q000000981:diagnostic imaging*; D008795:Metronidazole / Q000031:analogs & derivatives* / Q000138:chemical synthesis; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000138:chemical synthesis; D009593:Nitroimidazoles / Q000138:chemical synthesis; D011868:Radioisotopes; D011877:Radionuclide Imaging; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D009593:Nitroimidazoles; D011868:Radioisotopes; C031843:fluoromisonidazole; C050612:1-(2-fluoroethyl)-2-nitroimidazole; C050611:1-(2-fluoroethyl)-2-methyl-5-nitroimidazole; D008795:Metronidazole; D005461:Fluorine; D008920:Misonidazole